# Kenneth Cornetta

## List of Publications by Citations



| | | | |
|---|---|---|---|
| 38 papers | 1,662 citations | 13 h-index | 40 g-index |
| 41 ext. papers | 1,866 ext. citations | 6.5 avg, IF | 3.74 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 38 | Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. *New England Journal of Medicine*, **1990**, 323, 570-8 | 59.2 | 1042 |
| 37 | Umbilical cord blood transplantation in adults: results of the prospective Cord Blood Transplantation (COBLT). *Biology of Blood and Marrow Transplantation*, **2005**, 11, 149-60 | 4.7 | 118 |
| 36 | Preclinical demonstration of lentiviral vector-mediated correction of immunological and metabolic abnormalities in models of adenosine deaminase deficiency. *Molecular Therapy*, **2014**, 22, 607-622 | 11.7 | 64 |
| 35 | Tandem high dose chemotherapy with autologous bone marrow transplantation for initial relapse of testicular germ cell cancer. *Cancer*, **1997**, 79, 1605-10 | 6.4 | 63 |
| 34 | Absence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell Products. *Molecular Therapy*, **2018**, 26, 280-288 | 11.7 | 53 |
| 33 | Balancing personalized medicine and personalized care. *Academic Medicine*, **2013**, 88, 309-13 | 3.9 | 52 |
| 32 | Preclinical safety and efficacy of an anti-HIV-1 lentiviral vector containing a short hairpin RNA to CCR5 and the C46 fusion inhibitor. *Molecular Therapy - Methods and Clinical Development*, **2014**, 1, 11 | 6.4 | 41 |
| 31 | Replication-competent lentivirus analysis of clinical grade vector products. *Molecular Therapy*, **2011**, 19, 557-66 | 11.7 | 40 |
| 30 | Chronic myelogenous leukaemia CD34+ cells exit G0/G1 phases of cell cycle more rapidly than normal marrow CD34+ cells. *British Journal of Haematology*, **1998**, 102, 759-67 | 4.5 | 35 |
| 29 | Design and Potential of Non-Integrating Lentiviral Vectors. *Biomedicines*, **2014**, 2, 14-35 | 4.8 | 25 |
| 28 | Regulatory issues for clinical gene therapy trials. *Human Gene Therapy*, **2002**, 13, 1143-9 | 4.8 | 17 |
| 27 | Screening Clinical Cell Products for Replication Competent Retrovirus: The National Gene Vector Biorepository Experience. *Molecular Therapy - Methods and Clinical Development*, **2018**, 10, 371-378 | 6.4 | 15 |
| 26 | Resistance to human immunodeficiency virus type 1 (HIV-1) generated by lentivirus vector-mediated delivery of the CCR5{Delta}32 gene despite detectable expression of the HIV-1 co-receptors. *Journal of General Virology*, **2008**, 89, 2611-2621 | 4.9 | 14 |
| 25 | Lentiviral Gene Therapy with Autologous Hematopoietic Stem and Progenitor Cells (HSPCs) for the Treatment of Severe Combined Immune Deficiency Due to Adenosine Deaminase Deficiency (ADA-SCID): Results in an Expanded Cohort. *Blood*, **2019**, 134, 3345-3345 | 2.2 | 11 |
| 24 | Retroviral mediated gene transfer in chronic myelogenous leukaemia. *British Journal of Haematology*, **1994**, 87, 308-16 | 4.5 | 9 |
| 23 | AAV Joins the Rank of Genotoxic Vectors. *Molecular Therapy*, **2021**, 29, 418-419 | 11.7 | 9 |
| 22 | Transgenic sheep generated by lentiviral vectors: safety and integration analysis of surrogates and their offspring. *Transgenic Research*, **2013**, 22, 737-45 | 3.3 | 8 |

| | | | |
|---|---|---|---|
| 21 | Production of retroviral vectors for clinical use. *Methods in Molecular Biology*, **2008**, 433, 17-32 | 1.4 | 8 |
| 20 | Long-term outcomes after gene therapy for adenosine deaminase severe combined immune deficiency. *Blood*, **2021**, 138, 1304-1316 | 2.2 | 8 |
| 19 | IND-Enabling Studies for a Clinical Trial to Genetically Program a Persistent Cancer-Targeted Immune System. *Clinical Cancer Research*, **2019**, 25, 1000-1011 | 12.9 | 7 |
| 18 | Regulatory issues in human gene therapy. *Blood Cells, Molecules, and Diseases*, **2003**, 31, 51-6 | 2.1 | 5 |
| 17 | Equitable Access to Gene Therapy: A Call to Action for the American Society of Gene and Cell Therapy. *Molecular Therapy*, **2018**, 26, 2715-2716 | 11.7 | 5 |
| 16 | Retroviral gene therapy in hematopoietic diseases. *Journal of Clinical Apheresis*, **1997**, 12, 187-93 | 3.2 | 3 |
| 15 | Safety of Retroviral Vectors: Regulatory and Technical Considerations277-288 | | 2 |
| 14 | The National Gene Vector Biorepository's Pharm/Tox Database. *Molecular Therapy*, **2009**, 17, 582-4 | 11.7 | 1 |
| 13 | De Novo Synthesis & Storage of Human Factor VIII In Platelets Reduces Bleeding In Canine Hemophilia A. *Blood*, **2010**, 116, 2198-2198 | 2.2 | 1 |
| 12 | The National Gene Vector Biorepository: Eleven Years of Providing Resources to the Gene Therapy Community. *Human Gene Therapy*, **2020**, 31, 145-150 | 4.8 | 1 |
| 11 | Transitioning from development to commercial: risk-based guidance for critical materials management in cell therapies. *Cytotherapy*, **2020**, 22, 669-676 | 4.8 | 1 |
| 10 | Murine Leukemia Virus-Based Retroviral Vectors7-17 | | 1 |
| 9 | Development and Evaluation of Quality Metrics for Bioinformatics Analysis of Viral Insertion Site Data Generated Using High Throughput Sequencing. *Biomedicines*, **2014**, 2, 195-210 | 4.8 | 0 |
| 8 | Mutation In Erythroid Specific Transcription Factor KLF1 Causes Hereditary Spherocytosis In the Nan (Neonatal Anemia) Hemolytic Anemia Mouse Model. *Blood*, **2010**, 116, 3217-3217 | 2.2 | 0 |
| 7 | Gene Transfer to HSCs: Finding the Leukemia in Murine Leukemia Viruses. *Molecular Therapy*, **2019**, 27, 1072-1073 | 11.7 | |
| 6 | Reconstitution of Neutrophil NADPH Oxidase Activity in Murine X-CGD Following Transplantation of Retrovirus-Transduced Marrow: Potential Impact of Submyeloablative Conditioning.. *Blood*, **2005**, 106, 3050-3050 | 2.2 | |
| 5 | Biased Engraftment of Retrovirus-Transduced Marrow in Murine X-CGD Following Submyeloablative Conditioning.. *Blood*, **2006**, 108, 3285-3285 | 2.2 | |
| 4 | Cyclosporine Versus Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis after Matched Related and Unrelated Minimal Intensity Allotransplantation.. *Blood*, **2007**, 110, 5014-5014 | 2.2 | |

| | | |
|---|---|---|
| 3 | Replication-Competent Lentivirus Analysis of Vector-Transduced T Cell Products Used in Cancer Immunotherapy Clinical Trials. *Methods in Molecular Biology*, **2020**, 2086, 181-194 | 1.4 |
| 2 | The Access Technology Program of the Indiana Clinical Translational Sciences Institute (CTSI): A model to facilitate access to cutting-edge technologies across a state. *Journal of Clinical and Translational Science*, **2020**, 5, e33 | 0.4 |
| 1 | Use of a Novel Trigger Tool to Identify Palliative Care Needs in Surgical Patients at a National Referral Hospital in Kenya: A Pilot Study. *Journal of Palliative Medicine*, **2021**, 24, 1455-1460 | 2.2 |